Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the social anxiety disorder drug market will triple sales volume by 2012 primarily as a result of an increase in the size of the drug-treated population and the approval of more agents to treat the condition.

"Though the growth trend for the SAD market that started with the approval of paroxetine in 1999 will continue, SAD will remain one of the smallest of the psychiatric markets," said Anathea Waitekus, analyst Decision Resources. "The SAD market will only boast sales of $2 billion by 2012 because most SAD sufferers will not be diagnosed and treated for the condition, either because they fail to present for treatment or because they are diagnosed and treated for another comorbid disorder such as depression or panic that is more easily recognized."

The new Pharmacor study entitled Social Anxiety Disorder also found that Pfizer's pregabalin will be a welcome alternative to patients who can not tolerate sexual dysfunction from SSRIs and SNRIs, the leading agents in treatment of SAD.

Disease Facts - Social Anxiety Disorder

SAD offers immense market opportunity because it is one of the most common psychiatric disorders. Yet, this opportunity remains untapped because the population of SAD sufferers remains severely undiagnosed and untreated. Suffers of SAD are too often diagnosed with a comorbid condition that has developed, sometimes decades later, after the onset of their SAD. By the time they are diagnosed with the comorbid condition it is often too late to repair the damage SAD has done. The debilitating effects of SAD can prevent its sufferers from reaching their educational, occupational, financial, and social potential.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Social Anxiety Disorder is a Psychiatric Disorders study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Ion-Channel Modulators Have Significant Clinical and Commercial Potential in Treating Central Nervous System Diseases, Cardiovascular Diseases, and Cancer

View Now